All possible combinations of two or three PSG genes (45 and 120 combinations, respectively) were assessed by defining a tumor sample as PSG− (70.1%, 190/271) if all PSG genes in a combination had no expression and otherwise defining it as PSG+ (29.9%, 81/271). This evidence concerns the gene PSG5 and neoplasm.